...
CNTAMID

Centessa Pharmaceuticals plc

HealthcareBiotechnology
$26.86
$0.00(+0.34%)
52W$9.60
$30.58
FinancialsValuationvs REGN
Updated Mar 1, 12:00 AM
RSI66
RS Rating87/99
Beta0.98
Volatility58%
F-Score3/9
Mkt Cap$3.6B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Centessa Pharmaceuticals plc is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 87), indicating clear outperformance against the broad market. Earnings contraction of 11% provides fundamental context to the price action. Investors should exercise caution due to high volatility (58% annualized), which requires wider risk management.

Relative Strength
87
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.98
vs S&P 500
MARKET
52W Position
82%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$24.40
50 SMA > 100 SMA$24.99
100 SMA > 150 SMA$23.08
150 SMA > 200 SMA$20.68

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$24.93+7.72%ABOVE
50 SMA$24.40+10.06%ABOVE
100 SMA$24.99+7.47%ABOVE
150 SMA$23.08+16.40%ABOVE
200 SMA$20.68+29.87%ABOVE

Price Performance

1D+0.3%
1W+5.4%
1M+6.4%
3M-7.5%
6M+62.2%
YTD+13.4%
1Y+72.7%
3Y+96.9%
52-Week Trading Range82% from low
$26.86
52W Low$9.60
52W High$30.58

Technical Indicators

RSI (14)BULLISH
65.7
305070
VCP ScoreCOOL
5/10
Base depth: 33.8%

Risk Profile

Beta
0.98
52W Vol
58%
ATR
$1.12
Max DD (1Y)
-38%

Volume Analysis

Today
26
50D Avg
1.17M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24-121%
$-0.84
Q1'25+47%
$-0.20
Q2'25+5%
$-0.38
Q3'25-11%
$-0.41
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+118.88%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-19.61%

Stock Price CAGR

10 Years:+2.13%
5 Years:+4.31%
3 Years:+96.87%
1 Year:+72.73%

Return on Equity

10Y Avg:-135.5%
5Y Avg:-135.5%
3Y Avg:-59.7%
Last Year:-80.5%

Key Metrics

Market Cap$3.6B
Gross Margin—
Net Margin—
Piotroski F-Score3/9

More CNTA Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CNTA vs REGNREGNIMNMCLDXRXRX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 87 meansCNTA outperformed 87% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.98 means 2% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is CNTA in an uptrend right now?

CNTA has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is CNTA overbought or oversold?

CNTA's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.

Is CNTA outperforming the market?

CNTA has a Relative Strength (RS) Rating of 87 out of 99. Yes, CNTA is a market leader, outperforming 87% of all stocks over the past 12 months.

Where is CNTA in its 52-week range?

CNTA is trading at $26.86, which is 88% of its 52-week high ($30.58) and 82% above its 52-week low ($9.60).

How volatile is CNTA?

CNTA has a Beta of 0.98 and 52-week volatility of 58%. It's less volatile than the S&P 500 - generally more stable.